/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

ALIGOS THERAPEUTICS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$9.7868 0.0717(7.17%) ALGS at 04 Dec 2025 04:25 PM Biotechnology
Lowest Today 9.22
Highest Today 9.8
Today’s Open 9.22
Prev. Close 9.21
52 Week High 46.80
52 Week Low 3.76
Day’s Range: Low 9.22 High 9.8
52-Week Range: Low 3.76 High 46.80
1 day return -
1 Week return +4.06
1 month return +37.08
3 month return -6.98
6 month return +61.22
1 year return -61.37
3 year return +973.11
5 year return -42.11
10 year return -

Institutional Holdings

Woodline Partners LP 7.46

Deep Track Capital, LP 6.39

Alyeska Investment Group, L.P. 5.93

Sio Capital Management, LLC 4.83

TANG CAPITAL MANAGEMENT LLC 2.03

Adage Capital Partners Gp LLC 2.01

Vanguard Group Inc 2.01

Readystate Asset Management LP 1.97

Vanguard Total Stock Mkt Idx Inv 1.40

Baker Bros Advisors LP 1.19

Hillhouse Capital Advisors, Ltd. 1.10

Renaissance Technologies Corp 0.76

Vanguard Institutional Extnd Mkt Idx Tr 0.61

Geode Capital Management, LLC 0.49

LPL Financial Corp 0.43

Charles Schwab Investment Management Inc 0.37

Schwab US Small-Cap ETF™ 0.37

Fidelity Extended Market Index 0.33

Squarepoint Ops LLC 0.27

Citadel Advisors Llc 0.22

XTX Topco Ltd 0.20

Wells Fargo & Co 0.20

BlackRock Inc 0.19

Millennium Management LLC 0.18

Fidelity Series Total Market Index 0.12

Fidelity Total Market Index 0.11

Spartan Extended Market Index Pool F 0.08

Extended Equity Market Fund K 0.08

Northern Trust Extended Eq Market Idx 0.04

NT Ext Equity Mkt Idx Fd - L 0.04

Spartan Total Market Index Pool G 0.04

NT Ext Equity Mkt Idx Fd - NL 0.03

Fidelity Nasdaq Composite Index 0.03

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.02

Avantis US Small Cap Equity ETF 0.02

Vanguard U.S. Eq Idx £ Acc 0.01

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.01

NT Ext Eq Mkt Indx Fd DC Lend T3 0.01

Extended Equity Market Fund M 0.01

ZWJ Balanced 0.01

Market Status

Strong Buy: 2

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 56.67 M

PB Ratio 0.8207

PE Ratio 0.0

Enterprise Value -34.08 M

Total Assets 70.09 M

Volume 52705

Company Financials

Annual Revenue FY23:15529000 15.5M, FY22:13907000 13.9M, FY21:4359000 4.4M, FY20:-10548000 -10.5M, FY19:0 0.0M

Annual Profit FY23:12460000 12.5M, FY22:13907000 13.9M, FY21:4359000 4.4M, FY20:-10548000 -10.5M, FY19:null 0.0M

Annual Net worth FY23:-87679000 -87.7M, FY22:-96046000 -96.0M, FY21:-128332000 -128.3M, FY20:-108543000 -108.5M, FY19:-52264000 -52.3M

Quarterly Revenue Q3/2025:741000 0.7M, Q2/2025:965000 1.0M, Q1/2025:311000 0.3M, Q3/2024:1269000 1.3M, Q2/2024:1061000 1.1M

Quarterly Profit Q3/2025:741000 0.7M, Q2/2025:706000 0.7M, Q1/2025:311000 0.3M, Q3/2024:1269000 1.3M, Q2/2024:451000 0.5M

Quarterly Net worth Q3/2025:-31537000 -31.5M, Q2/2025:-15863000 -15.9M, Q1/2025:43088000 43.1M, Q3/2024:-19259000 -19.3M, Q2/2024:5061000 5.1M

Fund house & investment objective

Company Information Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Organisation Biotechnology

Employees 70

Industry Biotechnology

CEO Dr. Lawrence M. Blatt MBA, Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow